Credit: Shutterstock A committee of nephrologists and cardiologists developed 6 recommendations to improve hyperkalemia management. Patients with chronic kidney disease, heart failure, and diabetes ...
Hyperkalemia was more common among older women treated with spironolactone for a skin condition, and among those with comorbidities, but cases were usually mild and rarely altered care, a study ...
ROCKVILLE, Md., July 11, 2024 (GLOBE NEWSWIRE) -- The American Kidney Fund (AKF) today launched patient-focused guidelines to help people with chronic kidney disease (CKD) manage and treat ...
Although serum potassium monitoring is recommended to reduce the risk of hyperkalemia, only a small percentage of patients taking RAAS inhibitors are monitored. Hyperkalemia diagnosis is often missed ...
Hyperkalemia is associated with increased mortality risk. A recent study examined whether rapid correction of elevated serum potassium level (K+) was associated with reduced mortality in patients ...
Guidelines support the use of RAASi at the maximum tolerated dose in patients with CKD and heart failure. Cardiorenal risks increase following discontinuation or downtitration of ...
In patients with type 2 diabetes (T2D), the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with lower rates of hyperkalemia and sustained use of guideline-recommended renin ...
WILMINGTON, Del.--(BUSINESS WIRE)--Today, the US Food and Drug Administration (FDA) approved a label update in the US for AstraZeneca’s LOKELMA ® (sodium zirconium cyclosilicate) to include a dosing ...
Please provide your email address to receive an email when new articles are posted on . Improved potassium levels impacted the physical and/or mental well-being of patients managing hyperkalemia, ...
Please provide your email address to receive an email when new articles are posted on . Patients with a urine albumin-creatinine ratio of at least 3,500 mg/g had high rates of hyperkalemia. High rates ...
WASHINGTON, DC—The oral potassium-binding agent patiromer (Veltassa; Vifor Pharma) may help keep hyperkalemia under control in heart failure with reduced ejection fraction (HFrEF) patients taking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results